1979 - The Company was incorporated on 11th July, and the Certificate of
Commencement of Business was obtained on 6th November, 1979. It
was promoter jointly by Astra Pharmaceuticals AB, Sweden (Astra)
and IDL Chemicals Ltd., Hyderabad (IDL).
1980 - The Company entered into a technical collaboration with Astra
Pharmaceuticals AB, Sweden for the supply for information and
know-how and all manufacturing process and technical data for the
manufacture of basic drugs, formulations, fine chemicals and
- The Company undertook to set up a project at Yelahanka,
Bangalore, for the manufacture of basic drugs, formulations, fine
and industrial chemicals. Pharmaceuticals and chemicals plant
was commissioned in February 1982.
1982 - 2,000 shares issued to promoters, etc. 24,98,000 shares issued at
par; 6,43,235 shares each allotted to Astra Pharmaceuticals AB,
Sweden and IDL Chemicals, Ltd.; 3,78,830 shares allotted to
Indian directors, shareholders and employees, shareholders and
employees, etc. of the company and also that of IDL Chemicals,
Ltd. and 8,32,700 shares offered for public subscription during
1988 - The Company launched `SENSORCAINE', a long acting local
anaesthetic for use in surgical anaesthesia and introduced
`THEOBRIC', a combination branco dilator for asthma. The Company
also planned to launch new products based on original research of
Astra in the fields of peptic ulcer, hypertension and asthma.
- The Company launched during the year `RESTOMYCIN', an antibiotic
`BROMENYL', a cough expectorant and `FEBRAFEN' a pain and fever
- The company was also in the process of creating in-house
facilities for the manufacture of products based on inhalation
therapy and formulation therapy and formulations based on
- The Company launched `PROSTODIN', the first protagladin with an
important indication for postpartum haemorage, etc. Several new
products were launched during the year, namely, SELOPRES, BETALOC
DURULES, TRIPRES, SENSORCAINE SPINAL and BRICANYL NEBULISING
SOLUTION. It also launched products based on inhalation therapy
such as `PULMICORTINHALER' BRICANYL INHALER and SPACEHALER.
1991 - The Company launched a product in the Prostaglandins range
`PIMIPROST' for the promotion of safe motherhood.
1992 - The Company launched Prostaglandin `Cerviprime Gel' for
preinduction cervical ripening and `Plendil' a new generation
calcium antagonist. The Company proposed to launch `Ramace',
`Rhinocort' and `Imdur'.
1994 - Several new products were launched during the year, namely,
Ramace and Imdur, which strengthen the cardiovascular range of
products. Similarly Rhinocort was introduced which is in the
range of respiratory care products.
1995 - 25,00,000 bonus shares issued in prop. 1:1.
1996 - Two new line of extension namely `Jumbo' pack of Pulmicort &
Bricanyl Inhalers 400 metered doses were introduced in the
respiratory group. A low dose aspirin formation to correct
thromboembolic disorders was launched. Also Imdur 30 mg to
support Imdur 60 mg was introduced.
1997 - A range of new products viz., Xylocaine Spray in pain control
segment, Stop-it in Anti-infective segment, Mimbid in NSAID
segment, Linctus-D and Rhinocort Aqua in Respiratory segment,
Rejois in Maternal health care segment and Cellubril, a stool
- The company established state-of-the-art production facilities
for aerosols and soft gelatin capsules near its formulations
- A joint venture between Astra AB of Sweden and IDL Industries
of the Hindujas, Astra-IDL has been the subject of a prolonged
litigation between the two promoters.
- A joint venture between the US $ 7-billion Swedish pharmaceutical
major Astra AB and IDL Industries of the Hindujas.
1998 - Wipro, Honda Siel Power Products, and Astra-IDL have been
conferred the Analyst Awards, by The Institute of Chartered
Financial Analysts of India (ICFAI).
- Astra had set up a 100 per cent research facility in Bangalore
three years ago.
1999 - Even as the Hindujas continue to seek new alignments to replace
multinational AstraZeneca in their joint venture Astra-IDL Ltd.
2000 - UB's 100 per cent subsidiary, UB Bioteck, has tied up with Astra
IDL Ltd to market its newly-patented anti-obesity nutraceutical.
- Mr. D.E. Udwadia, Director, has been appointed as the Chairman.
2001 - Crisil has placed the `FAA' rating on the fixed deposit programme of the
company on a `rating watch with positive implications'.
- The Company upon the acquisition, Astra, Swden now holds 51.50 per cent of the
company's issued and paid-up equity shares capital. The company is therefore
a subsidiary of Astra, Swden and has become a part of the worldwide AstraZeneca Group.
- The Managing Director, Mr. A.R. Hegde, has resigned from the company.
- Astra-IDL Ltd will be renamed AstraZeneca Pharma India Ltd and Mr Lars Walan,
recently designated Managing director, will take over on April 2 from Mr. A.R.
Hegde, MD, who has resigned.
-Ties up with Avestha for research on discovering drug for tuberculosis.
-Makes an open offer to acquire the balance 21,75,050 equity shares of Astrazeneca pharma India Ltd representing 43% stake.
-Government okays FDI proposal for the company and Tata Homefinance from 56.69% to 100% accounting for Rs.82 crs.
-Astra Pharma acquires 32800 equity shares of Astrazeneca.
-Astra Pharma and Astrazeneca jointly acquires less than 4% additional equity Astrazeneca Pharma India Ltd.
-Sri Tom McKillop, inaugurates R & D centre in Bangalore at a cost of $40 million.
-Approaches Union government for Exclusive Marketing Rights for new two generation anti-cancer drugs.
-Astrazeneca Pharma India Limited Board accepts resignation of Mr. J G Zetterberg, Director, effective from the close of May 05, 2004.
-AstraZeneca acquires Eli Lilly's Vancocin brand
-Company has splits its Face value of Shares from Rs 10 to Rs 2
-AstraZeneca Pharma India Ltd has appointed Mr. Ruud Dobber as Director of the Company.
- AstraZeneca Pharma and biopharmaceutical company Bristol-Myers Squibb launched their 9-month-old diabetes drug Onglyza in India - the biggest market for the drug.Onglyza, or saxagliptin, is used to treat type 2 diabetes in adults.
- AstraZeneca Pharma India Ltd has appointed Ms. Anita Zutshi as the Chief Financial Officer of the Company.
-AstraZeneca Halts Late-Stage Trial of Prostate Cancer Medicine Zibotentan
-Appointment of Mr. Himanshu Agarwal as the CFO of the Company
-AstraZeneca Excellence in Chemistry Awards 2011
-AstraZeneca and Cellworks Collaborate to find new Treatment for Tuberculosis
-AstraZeneca launches its patented life-saving heart drug BRILINTAÂ® (Ticagrelor) in India
-AstraZeneca to acquire Bristol-Myers Squibb share of global diabetes alliance assets
-AstraZeneca enters co-promotion agreement with Janssen in Japan for innovative prostate cancer treatment.
-AstraZeneca and Bristol-Myers Squibb Company today announced the US Food and Drug Administration (FDA) approved FARXIGAÂ (dapagliflozin).
-AstraZeneca and MRC enter strategic collaboration to create new centre for early drug discovery in Cambridge, UK .
-AstraZeneca and Roche announce partnership to develop companion diagnostic test for AZD9291
-The Registered Office of the Company has been shifted from 'Avishkar', Off Bellary Road, Hebbal, Bangalore - 560 024 to Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Outer Ring Road, Bangalore - 560 045.
-AstraZeneca Pharma India Limited and Dr ReddyÂs Laboratories Limited enter distribution agreement for saxagliptin and its fixed dose combination with metformin, in Type 2 Diabetes
-AstraZeneca Pharma launches type-2 diabetes treatment drug
-BRILIQUE (ticagrelor) receives positive European Union CHMP opinion for extended treatment of patients with a history of heart attack
-AstraZeneca completes acquisition of ZS Pharma
-AstraZeneca opens new manufacturing facility to support continued growth in Russia